Research Progress of Exercise Intervention on Breast Cancer: A Visualization Analysis
-
摘要:目的
分析“乳腺癌运动干预”领域的研究热点及趋势,以期为乳腺癌运动干预方案设置提供理论依据。
方法以Web of Science核心数据库近五年所收录的乳腺癌运动干预类的7 134篇文献为对象,运用CiteSpaceⅤ进行可视化知识图谱分析,生成可视化图谱包括学科分布、国家或地区分布、关键词共现或突显、关键词时间线图谱等进行分析。
结果近年“乳腺癌运动干预”领域得到了快速的发展,学科分布主要集中在心血管系统与心脏病学和肿瘤学等。美国、英格兰和意大利等国家发文量排名靠前。身体质量指数、生活质量中介中心性分别为0.81、0.52,在知识图谱中有着重要的地位。关键突显图谱和时间线图谱显示心脏毒性是该领域的研究热点。
结论乳腺癌运动干预研究热点主要集中在心血管及其相关领域,目前处于高速发展阶段。未来研究方向包括体重控制、生活质量和心脏毒性。
Abstract:ObjectiveTo analyze the research focuses and frontiers of exercise intervention on breast cancer patients.
MethodsWe collected 7134 pieces of literature about exercise intervention on breast cancer in the Web of Science Core Collection database in recent five years, and CiteSpaceⅤ was used to conduct visual knowledge map analysis and generate a visual map including discipline distribution, country or region distribution, keyword co-occurrence or highlighting, keyword timeline maps, etc.
ResultsIn recent years, the domain of exercise intervention on breast cancer has achieved rapid development. The disciplines were mainly cardiovascular system and cardiology as well as oncology. Countries such as the United States, the United Kingdom and Italy ranked in the first places with regard to the number of papers. The body mass index and the quality of life betweeness centrality were respectively 0.81 and 0.52, which played an important role in the knowledge map. The keyword highlighting map and the timeline map showed that cardiac toxicity was a research focus in this domain.
ConclusionThe research focuses of exercise intervention on breast cancer are mainly cardiovascular and related fields, in a rapid development stage. Future research directions include weight control, quality of life and cardiac toxicity.
-
Key words:
- Breast Cancer /
- Exercise intervention /
- CiteSpace /
- Visualization analysis /
- Exercise prescription
-
0 引言
子宫内膜癌是在北美和欧洲最常见的女性恶性肿瘤,近年来我国的发病率明显增加,发病人群年轻化[1]。子宫内膜癌的发病机制目前尚未完全明确,随着研究的深入,越来越清晰地认识到子宫内膜癌是多种因素协同交叉作用、具有不同遗传和分子特征的一类疾病[2-3]。根据肿瘤发病机制与雌激素依赖相关性,将其分为Ⅰ型和Ⅱ型,80%以上为Ⅰ型子宫内膜癌。遗传易感性是导致个体对相同致癌因素敏感度不一致的重要因素,某些雌激素代谢通路中关键酶可以改变体内雌激素或外源性雌激素及其代谢产物的水平。基因多态性与酶活性有关,雌激素代谢酶基因多态性可能导致子宫内膜癌发病易感性差异[4]。本研究利用SNP分型检测技术,探索雌激素代谢关键酶CYP1B1、CYP1A1和NQO1基因的单核苷酸多态性(single nucleotide polymorphisms, SNPs)位点分布频率与Ⅰ型子宫内膜癌易感性之间关系,以期对Ⅰ型子宫内膜癌的易感人群进行筛查。
1 资料与方法
1.1 临床资料
抽取我院2014年3月—2016年10月收治的经病理诊断为子宫内膜样腺癌的103例患者和同期子宫内膜正常的100例其他疾病患者静脉外周全血2~3 ml,作为检测标本。病例和对照组均取得患者的知情同意并详细询问病史,包括初潮年龄、生育状况、绝经年龄、孕产次数、内科并发症及肿瘤家族史。测量身高与体重,并计算体质指数(body mass index, BMI),测量血压,采集静脉血化验空腹血糖(FPG)及血脂、肿瘤标志物[5-6]。年龄31~78岁,平均(51.15±9.69)岁,子宫内膜癌组平均年龄(54.77±8.21)岁,对照组为(46.95±9.65)岁。
1.2 方法
1.2.1 确定候选基因及其SNPs位点
由于Ⅰ型子宫内膜癌为雌激素依赖性肿瘤,结合相关文献报道,在美国国家生物技术信息中心(National Center for Biotechnology Information, NCBI)人类基因组数据库中选择与雌激素代谢相关的关键酶CYP1A1、CYP1B1,具有抗癌突变的依赖还原型辅酶Ⅰ/Ⅱ醌氧化还原酶1(quinone oxido-reductase1, NQO1)3个基因,选取与代谢酶活性密切相关且杂合度大于10%的SNPs位点进行基因型分析。
1.2.2 引物设计合成
利用引物设计软件premier 5.0,在含SNPs的DNA序列上设计PCR引物,并将设计的引物进行引物的同源性比较,选出同源性最小而Tm值和G/C比值合适的引物作为PCR反应引物,所扩增片段应包含要检测的SNPs位点,其位置尽可能设计在PCR扩增片段的中部。
1.2.3 检测方法
使用DNA提取试剂盒(DP304-03)从外周血中提取DNA,进行预扩增,琼脂糖凝胶电泳检测DNA完整性。根据设计引物模板,进行延伸反应及延伸产物纯化。PCR扩增反应体系总体积为50 μl,内含5 μl 10×PCR缓冲液,3 μl 25 mmol/L MgCl2溶液,5 μl 2 mmol/L dNTP混合物,1.25 U Taq DNA聚合酶,0.5 μmol/L引物及100g的基因组DNA。反应在MJ公司PTC-100 PCR反应仪中进行。PCR循环条件为95℃预变性10 min,然后94℃变性30 s,60℃复性30 s,72℃延伸30 s,反应40个循环后,72℃再延伸10 min。扩增产物用2%的琼脂糖凝胶电泳检测,4℃保存。PCR产物经纯化后作为测序模板,用Big-Dye末端荧光标记试剂盒进行测序反应,测序反应产物经纯化后在ABI公司3730XL测序仪上进行测序电泳,用Gene codes公司的Sequencer4.2对测序结果进行分析。
1.3 统计学方法
采用SPSS18.0软件对实验数据进行统计学分析,用χ2检验和多因素Logistic回归模型分析各基因型在两组人群中的分布差异及其与子宫内膜癌临床病理特征的相关性,P < 0.05为差异有统计学意义。
2 结果
2.1 多因素回归分析
CYP1B1基因SNPs位点rs111888224因无碱基改变未纳入统计,rs1056836、rs2551188、rs10916在研究人群中均存在多态性,但分布频率差异无统计学意义;rs1056836 C、G基因分布频率差异有统计学意义(P=0.0454)。
CYP1A1基因SNP位点rs4646421在研究人群中存在CT、CC、TT多态性。与CT型相比,CC型为保护基因型,OR=0.479(95%CI: 0.255~0.899),差异有统计学意义(P=0.0219),其C、T基因分布频率差异有统计学意义(P=0.0041),见表 1。
表 1 基因型/等位基因在Ⅰ型子宫内膜癌患者中的分布(n(%))Table 1 Genotype/alleles distributions in typeⅠendometrial carcinoma cases (n(%))2.2 CYP1A1基因rs4646421位点多态性与Ⅰ型子宫内膜癌危险因素的分层分析
对CYP1A1基因rs4646421位点不同基因型与Ⅰ型子宫内膜癌的危险因素相关性进行分层比较,发现在年龄 > 60岁、BMI≥25、绝经延迟、并发高血压的个体中,携带CT+TT突变基因型将增加罹患Ⅰ型子宫内膜癌的风险(P < 0.05),见表 2。
表 2 发病危险因素与基因型分布的关系(n(%))Table 2 Association between risk factors and genotypes distributions of SNP(rs4646421) in CYP1A1 (n(%))3 讨论
雌激素分布在细胞内外表面,通过雌激素受体的核内结合蛋白在靶细胞中保持高亲和力和特异性。涉及雌激素生物合成和代谢的基因的多态性是雌激素受体阳性恶性肿瘤的潜在危险因素,有几种细胞色素P450(CYP)酶参与雌激素的氧化代谢途径[7]。CYP1A1和CYP1B1是代谢产生2-羟基-4-羟基雌激素代谢物的基本酶[8-9],在不同人群中不仅存在多态性,并且在性激素相关组织中的表达高于细胞色素P450超家族的其他成员,其基因多态性与乳腺癌、子宫肌瘤、子宫内膜异位症、宫颈癌等疾病风险相关[10-14]。
CYP1A1基因定位于人类染色体15q22-24,编码由512个氨基酸组成的蛋白质,是细胞色素P450家族中高诱导成员。CYP1A1酶的激活参与内源性和外源性化合物的氧化作用,催化多环芳香族碳氢化合物转化为酚与环氧化合物。一些酚类和环氧化合物可与DNA结合形成加合物,最终转化为致癌物、二醇环氧化物,通过环氧化物水解酶与一些抗肿瘤药物发生耐药,并增加个体肿瘤风险[9, 15]。本研究结果显示CYP1A1基因SNP位点rs4646421在子宫内膜癌人群中存在CT、CC、TT多态性,与携带CT基因型相比,携带CC基因型的个体罹患子宫内膜癌的风险较小,携带T等位基因的个体子宫内膜癌的发病风险高于C等位基因携带者。与携带CC基因型相比,携带TC+TT基因型在年龄 > 60岁、BMI≥25、绝经延迟(超过52岁)、合并高血压的女性中Ⅰ型子宫内膜癌的发病风险增加。
CYP1B1基因位于染色体2q21-22,其单核苷酸多态性SNP总数有353个,目前研究较多的是SNPrs1056836,其mRNA发生1294位碱基胞嘧啶(cytosine, C)变异为鸟嘌呤(guanine, G),使DNA两条链形成野生CC型,杂合CG型和变异GG型3种基因型,即基因多态性。这种改变导致第三外显子432密码子的碱基由CTG变异为GTG,由其编码的亮氨酸(leucine, Leu)变异为缬氨酸(valine, Val),导致CYP1B1酶蛋白功能的改变[16]。CYP1B1通过多方面影响肿瘤的易感性和预后,在胰岛素抵抗中产生作用,突变型表达的酶之蛋白质表现出更强的激活癌前物质活性,或影响睾酮的6β-羟化作用及性激素的激活代谢等[17-18]。
本研究中CYP1B1基因SNP rs2551188、rs10916两个位点在人群中存在多态性,但分布频率无统计学差异;rs1056836在正常子宫内膜组与子宫内膜癌两组间的基因型分布频率无差异,但发生更多的碱基胞嘧啶变异为鸟嘌呤,可能会使罹患子宫内膜癌的风险增加,以往文献中发现对于单个位点基因突变的表现为阴性结论时,多个位点联合的单倍体基因型研究却往往能得到阳性结论,似乎预示着CYP1B1基因在分子遗传学上有一定的倾向性[16-19],但其与肿瘤易感性及预后的机制问题还存在着诸多争议与疑惑,有待于进一步研究。
NQO1是一种重要的化学致癌物质代谢酶,具有抗癌作用,可使内源性及外源性醌类化合物通过电子还原反应变成低毒性的氢醌类物质,再转化为水溶性化合物排出体外,降低了细胞发生突变及癌变的概率。如果位点发生突变,使原位编码的氨基酸发生改变,将会导致该酶活性减弱或完全丧失,降低解毒功能且不能维护细胞稳定,增加某些易感个体细胞发生癌变[20]。报道显示NQO1蛋白高表达在卵巢癌、乳腺癌、结直肠癌等肿瘤中,与临床分期晚、分化程度差和淋巴结转移等临床特征有关[21-22],本研究选择的SNP位点rs45488899和rs1800566虽在两组间均存在基因多态性,但分布频率不具有差异性,因此认为这两个SNP位点与Ⅰ型子宫内膜癌的发生无显著相关性。
本研究通过基因表达谱差异的分析,推测CYP1A1基因rs4646421位点的多态性在Ⅰ型子宫内膜癌的发生发展中起着重要作用,可作为进行高危人群筛查的基因位点,还可以突变的基因型为基础,采取针对性的基因靶向治疗,或者通过修正基因突变谱来改善其预后。但是,基因多态性受复杂的遗传、环境因素、种族等的影响,并与样本量的大小有关,必须经过大样本试验来进一步明确基因多态性与子宫内膜癌易感性之间的基因环境交互作用及具体机制。
Competing interests: The authors declare that they have no competing interests.作者贡献:洪陈:数据收集及处理、CiteSpace的运行、知识图谱分析及论文撰写与修改彭鑫瑜:观察知识图谱的特征、论文撰写与修改郭吟:指导研究设计、审核数据及知识图谱、论文撰写与修改王静松:收集文献资料、论文修改 -
表 1 排名前10的高频学科
Table 1 Top 10 high-frequency disciplines
表 2 发文量排名前10的国家
Table 2 Top 10 countries in terms of number of published papers
表 3 排名前10的高频关键词
Table 3 Top 10 high-frequency keywords
-
[1] 张雅聪, 吕章艳, 宋方方, 等. 全球及我国乳腺癌发病和死亡变化趋势[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 14-20. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLZD202102002.htm Zhang YC, Lyu ZY, Song FF, et al. Trends in incidence and mortality of breast cancer worldwide and in China[J]. Zhong Liu Zong He Zhi Liao Dian Zi Za Zhi, 2021, 7(2): 14-20. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLZD202102002.htm
[2] Campbell KL, Winters-Stone KM, Wiskemann J, et al. Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable[J]. Med Sci Sports Exerc, 2019, 51(11): 2375-2390. doi: 10.1249/MSS.0000000000002116
[3] Scott JM, Thomas SM, Peppercorn JM, et al. Effects of Exercise Therapy Dosing Schedule on Impaired Cardiorespiratory Fitness in Patients With Primary Breast Cancer: A Randomized Controlled Trial[J]. Circulation, 2020, 141(7): 560-570. doi: 10.1161/CIRCULATIONAHA.119.043483
[4] 刘洋, 王德新, 程丽芬, 等. 基于运动生物力学视角研究运动性疲劳干预方案的可视化知识图谱分析[J]. 中国组织工程研究, 2019, 23(27): 4291-4299. doi: 10.3969/j.issn.2095-4344.1374 Liu Y, Wang DX, Cheng LF, et al. Visualization analysis of Citespace V on sports fatigue protocols from the perspective of sports biomechanics[J]. Zhongguo Zu Zhi Gong Cheng Yan Jiu, 2019, 23(27): 4291-4299. doi: 10.3969/j.issn.2095-4344.1374
[5] 金成吉, 付加宁, 饶刘. 基于知识图谱的国内外运动生物力学研究热点分析[J]. 湖北体育科技, 2019, 38(8): 701-704, 709. doi: 10.3969/j.issn.1003-983X.2019.08.010 Jin CJ, Fu JY, Rao L. Research Hotspot of Domestic and International Sports Biomechanics Based on Knowledge Map[J]. Hubei Ti Yu Ke Ji, 2019, 38(8): 701-704, 709. doi: 10.3969/j.issn.1003-983X.2019.08.010
[6] 李慧军, 魏翠兰, 李垂坤, 等. Citespace软件可视化分析运动与认知[J]. 中国组织工程研究, 2020, 24(14): 2277-2283. doi: 10.3969/j.issn.2095-4344.2465 Li HJ, Wei CL, Li CK, et al. Sports and cognition: a visual analysis using Citespace software[J]. Zhongguo Zu Zhi Gong Cheng Yan Jiu, 2020, 24(14): 2277-2283. doi: 10.3969/j.issn.2095-4344.2465
[7] Bradshaw PT, Stevens J, Khankari N, et al. Cardiovascular disease mortality among breast cancer survivors[J]. Epidemiology, 2016, 27(1): 6-13. doi: 10.1097/EDE.0000000000000394
[8] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[9] FanL, Strasser-Weippl K, Li JJ, et al. Breast Cancer in China[J]. Lancet Oncol, 2014, 15(7): e279-e289. doi: 10.1016/S1470-2045(13)70567-9
[10] Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body fatness and cancer-viewpoint of the IARC working group[J]. N Engl J Med, 2016, 375(8): 794-798. doi: 10.1056/NEJMsr1606602
[11] Chiurazzi M, Cozzolino M, Orsini RC, et al. Impact of Genetic Variations and Epigenetic Mechanisms on the Risk of Obesity[J]. Int J Mol Sci, 2020, 21(23): 9035. doi: 10.3390/ijms21239035
[12] Saleh K, Carton M, Dieras V, et al. Impact of body mass index on overall survival in patients with metastatic breast cancer[J]. Breast, 2021, 55: 16-24. doi: 10.1016/j.breast.2020.11.014
[13] Caan BJ, Cespedes Feliciano EM, Prado CM, et al. Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer[J]. JAMA Oncol, 2018, 4(6): 798-804. doi: 10.1001/jamaoncol.2018.0137
[14] Onishi S, Tajika M, Tanaka T, et al. Prognostic signifificance of sarcopenia in patients with unresectable Advanced esophageal cancer[J]. J Clin Med, 2019, 8(10): 1647. doi: 10.3390/jcm8101647
[15] Koene RJ, Prizment AE, Blaes A, et al. Shared risk factors in cardiovascular disease and cancer[J]. Circulation, 2016, 133(11): 1104-1114. doi: 10.1161/CIRCULATIONAHA.115.020406
[16] Beaudry RI, Kirkham AA, Thompson RB, et al. Exercise Intolerance in Anthracycline-Treated Breast Cancer Survivors: The Role of Skeletal Muscle Bioenergetics, Oxygenation, and Composition[J]. Oncologist, 2020, 25(5): e852-e860. doi: 10.1634/theoncologist.2019-0777
[17] Foulkes SJ, Howden EJ, Antill Y, et al. Exercise as a diagnostic and therapeutic tool for preventing cardiovascular morbidity in breast cancer patients- the BReast cancer EXercise InTervention (BREXIT) trial protocol[J]. BMC Cancer, 2020, 20(1): 655. doi: 10.1186/s12885-020-07123-6
[18] Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional Adipose Distribution and its Relationship to Exercise Intolerance in Older Obese Patients Who Have Heart Failure With Preserved Ejection Fraction[J]. JACC Heart Fail, 2018, 6(8): 640-649. doi: 10.1016/j.jchf.2018.06.002
[19] Forman DE, Arena R, Boxer R, et al. Prioritizing functional capacity as a principal end point for therapies oriented to older adults with cardiovascular disease: a scientific statement for healthcare professionals from the American Heart Association[J]. Circulation, 2017, 135(16): e894-e918. https://pubmed.ncbi.nlm.nih.gov/28336790/
[20] Malhotra R, Bakken K, D'Elia E, et al. Cardiopulmonary Exercise Testing In Heart Failure[J]. JACC Heart Fail, 2016, 4(8): 607-616. doi: 10.1016/j.jchf.2016.03.022
[21] Lu G, Zheng J, Zhang L. The effect of exercise on aromatase inhibitor-induced musculoskeletal symptoms in breast cancer survivors: a systematic review and meta-analysis[J]. Support Care Cancer, 2020, 28(2): 1587-1596. https://pubmed.ncbi.nlm.nih.gov/31853701/
[22] Raptopoulos Z, Constantinou C. The Effect of Exercise on the Alleviation of Side Effects Induced by Aromatase Inhibitors in Postmenopausal Breast Cancer Patients[J]. Curr Oncol Rep, 2020, 22(11): 110. doi: 10.1007/s11912-020-00971-2
[23] Scott JM, Thomas SM, Peppercorn JM, et al. Effects of Exercise Therapy Dosing Schedule on Impaired Cardiorespiratory Fitness in Patients With Primary Breast Cancer: A Randomized Controlled Trial[J]. Circulation, 2020, 141(7): 560-570. doi: 10.1161/CIRCULATIONAHA.119.043483
[24] 张宁宁. 中等强度运动对不同糖代谢人群心血管指标影响的研究[D]. 北京: 北京体育大学, 2018. Zhang NN. Study on the effect moderate intensity exercise on cardiovascular indexes in different glucose metabolism groups[D]. Beijing: Beijing Sport University, 2018.
[25] Brahmbhatt P, Sabiston CM, Lopez C, et al. Feasibility of Prehabilitation Prior to Breast Cancer Surgery: A Mixed-Methods Study[J]. Front Oncol, 2020, 10: 571091. doi: 10.3389/fonc.2020.571091
[26] Kirkham AA, Gelmon KA, Van Patten CL, et al. Impact of Exercise on Chemotherapy Tolerance and Survival in Early-Stage Breast Cancer: A Nonrandomized Controlled Trial[J]. J Natl Compr Canc Netw, 2020, 18(12): 1670-1677. doi: 10.6004/jnccn.2020.7603
[27] Maddocks M. Physical activity and exercise training in cancer patients[J]. Clin Nutr ESPEN, 2020, 40: 1-6. doi: 10.1016/j.clnesp.2020.09.027
[28] Sasso JP, Eves ND, Christensen JF, et al. A framework for prescription in exercise-oncology research[J]. J Cachexia Sarcopenia Muscle, 2015, 6(2): 115-124. doi: 10.1002/jcsm.12042
[29] Garralda E, Dienstmann R, Piris-Giménez A, et al. New clinical trial designs in the era of precision medicine[J]. Mol Oncol, 2019, 13(3): 549-557. doi: 10.1002/1878-0261.12465